Replimune Group, Inc. reported a net loss of $(313.94)M for the fiscal year ended March 31, 2026, compared with a $(247.30)M net loss in fiscal 2025, as the company recorded no product revenue while investing in research, development and commercial readiness — 10-K Summary.
Financial Highlights
- Revenue: $0 for FY 2026 and $0 for FY 2025 (no product revenue; no approved products).
- Net income: $(313.94)M net loss for FY ended Mar 31, 2026, versus $(247.30)M net loss in FY 2025; loss increased by (27%).
- Diluted EPS: Not disclosed as a consolidated diluted EPS figure in the MD&A only consolidated net loss amounts provided.
Business Highlights
- R&D expansion: Research and development spending increased about 17% year over year to advance lead programs RP1, RP2 and RP3 and to support the IGNYTE‑3 and REVEAL trials.
- Clinical progress: Enrollment ramped for the IGNYTE‑3 confirmatory study and the REVEAL trial; CERPASS and certain cohorts were wound down.
- Commercial readiness: The company built pre‑launch commercial infrastructure and increased headcount in preparation for a potential RP1 launch.
- Liquidity outlook: Management expects cash to fund operations through Q1 2027 under the current plan, focusing near term on the FDA pathway and program prioritization.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.